Marketed Products

Featured Marketed Products

Kyprolis

Kyprolis® (carfilzomib) for Injection is a Proteosome inhibitor indicated for the treatment of patients with multiple myeloma.

At a Glance

Licensee Indication Royalty
Amgen Multiple Myeloma 1.5-3.0%

EVOMELA

Captisol-enabled formulation of Melphalan which is used for stem cell transplant conditioning in multiple myeloma. Captisol improves product stability and enables the removal of propylene glycol, which is associated with renal and cardiac toxicities.

At a Glance

Partner Indication Royalty
Spectrum Oncology 20%

RYLAZE

RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen given by intramuscular injection for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.

At a Glance

Licensee Indication Royalty
Jazz Oncology 3-5%

Teriparatide

Teriparatide Injection is a prescription medicine used in both men and postmenopausal women with osteoporosis who are at high risk for having bone fractures

At a Glance

Licensee Indication Royalty
Alvogen Osteoporosis 25-50%

VAXNEUVANCE

VAXNEUVANCE is a vaccine to help protect against invasive disease caused by 15 types of pneumococcus, a kind of bacteria, in individuals 6 weeks of age and older. Invasive disease is a serious form of pneumococcal disease.

At a Glance

Licensee Indication Royalty
Merck Pneumococcal disease prevention low single-digit

PNEUMOSIL

PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, yet more affordable than the existing PCVs and provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.

At a Glance

Licensee Indication Royalty
Serum Institute of India Pneumococcal disease prevention low single-digit

Additional Marketed Products

Baxdela

Novel antibiotic indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

At a Glance

Partner Indication Royalty
Melinta Therapeutics Infectious Disease 2.5%

IV Voriconazole

Captisol-enabled IV formulation of voriconazole

At a Glance

Partner Indication Royalty
Alvogen Infectious Disease Material sales only

Duavee

DUAVEE (conjugated estrogens/bazedoxifene) is a progesterone-free treatment for moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and aids in the prevention of postmenopausal osteoporosis.

At a Glance

Partner Indication Royalty
Pfizer Menopause 0.5-2.5%

Viviant/Conbriza

Viviant/Conbriza™ (bazedoxifene) is a synthetic drug that was specifically designed to reduce the risk of osteoporotic fractures, while at the same time protecting breast and uterine tissue.

At a Glance

Partner Indication Royalty
Pfizer Osteoporosis 0.5-2.5%

Nexterone

NEXTERONE (amiodarone HCl) Premixed Injection is indicated for initiation of treatment and prophylaxis for frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to the therapy.

At a Glance

Partner Indication Royalty
Baxter Arrhythmia Undisclosed

Noxafil-IV

Captisol-enabled IV formulation of Noxafil

At a Glance

Partner Indication Royalty
Merck Infectious Disease Material sales only

ZULRESSO™

ZULRESSO, the first medicine specifically approved by the U.S. Food and Drug Administration for the treatment of postpartum depression, is an allosteric modulator of both synaptic and extrasynaptic GABAA receptors. Allosteric modulation of neurotransmitter receptor activity results in varying degrees of desired activity rather than complete activation or inhibition of the receptor. ZULRESSO is approved by the FDA for the treatment of PPD in adults, pending DEA scheduling. ZULRESSO has been granted PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA). We have the potential to receive milestone payments, royalties and revenue from Captisol material sales for Captisol-enabled programs. SAGE is responsible for all development costs related to the program.

At a Glance

Partner Indication Royalty
Sage Therapeutics CNS 3%

VEKLURY

Captisol-enabled formulation of Veklury

At a Glance

Partner Indication Royalty
Gilead Sciences Infectious Disease Material sales only